

PRIOR AUTHORIZATION REQUEST FORM

OXLUMO™

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Oxlumo™ (lumasiran)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Is the request made by, or in consultation with, a physician who specializes in the treatment of primary hyperoxaluria type 1 (PH1)?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does the member have a diagnosis of PH1 confirmed by both of the following: <ul style="list-style-type: none"> • Metabolic testing shows elevated urinary oxalate excretion persistently > 0.7mmol/1.73m²/day OR for those less than 6 years of age a urinary oxalate/serum creatinine ratio > the ULN for the member's age • Genetic testing confirms a mutation in the alanine glyoxylate aminotransferase (AGXT) gene 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Has the member received a liver transplant?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Has the prescriber educated the member about diet, such as avoiding oxalate rich foods (e.g. chocolate, leafy green vegetables, black teas, nuts, star fruit)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Has the member tried and failed, or has a contraindication/intolerance to, large fluid intake resulting in a high urinary output (> 3 L/day/1.73m ²)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Has the member tried and failed, is currently taking, or has a contraindication/intolerance to, calcium-oxalate crystallization	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

inhibitors (e.g. potassium citrate-citric acid, orthophosphate, magnesium oxide)?			
7. Has the member tried and failed, is currently taking, or has a contraindication/intolerance to, pyridoxine (Vitamin B6) for ≥ 3 months without a positive response (defined as a reduction of > 30% in urinary oxalate excretion)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member had a positive response to therapy with a significant reduction from baseline in urinary oxalate levels or for those <6 years of age a decrease in urinary oxalate/serum creatinine ratio?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Has the member experienced unacceptable drug toxicity to therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Has the member received a liver transplant?	<input type="checkbox"/>	<input type="checkbox"/>	
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy PHARM-M035
 Origination Date: 12/20/2020
 Reviewed/Revised Date: 05/18/2022
 Next Review Date: 05/18/2023
 Current Effective Date: 06/01/2022

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.